Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) Director Michael G. Grey sold 14,216 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $32.00, for a total value of $454,912.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Mirum Pharmaceuticals Stock Up 8.0 %
Shares of NASDAQ MIRM opened at $32.36 on Friday. Mirum Pharmaceuticals, Inc. has a 52-week low of $17.32 and a 52-week high of $32.53. The firm has a fifty day moving average of $26.45 and a 200-day moving average of $25.95. The company has a debt-to-equity ratio of 3.89, a current ratio of 6.59 and a quick ratio of 6.44.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its earnings results on Thursday, August 3rd. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.11). The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $30.00 million. Mirum Pharmaceuticals had a negative net margin of 152.27% and a negative return on equity of 103.59%. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -2.41 EPS for the current year.
Hedge Funds Weigh In On Mirum Pharmaceuticals
Analysts Set New Price Targets
MIRM has been the subject of several recent analyst reports. Raymond James lifted their target price on shares of Mirum Pharmaceuticals from $79.00 to $84.00 and gave the stock a “strong-buy” rating in a research note on Monday, August 21st. HC Wainwright reissued a “buy” rating and set a $63.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Five stocks we like better than Mirum Pharmaceuticals
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- Build a Solid Gold Retirement With AI Powerhouse Adobe
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
- The 3 Best Blue-Chip Stocks to Buy Now
- WeWork Stock Soars: Meme Stock Madness or Mirage?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.